CNS Pharmaceuticals, Inc.
NASDAQCNS Pharmaceuticals has become one of the most charged short-selling situations in the small-cap biotech universe this week, with a violent price surge colliding head-on with a rapidly building short position and a borrow market in near-crisis. The story starts with the stock itself. CNSP has gained 216% over the past month, closing Tuesday at $7.15 — up from levels…
CNSP short interest
Full pulse commentary is for ORTEX subscribers. The live data picture for CNSP below stays open — short interest, options flow, signals, and historical context.
Sign up free to read pulse →Short interest % of float, cost to borrow, utilization, and put/call ratio for CNSP are part of the ORTEX premium tier. Sign up to read the live numbers alongside the analysis.
Snapshot as of 6 May 2026
CNS Pharmaceuticals has become one of the most charged short-selling situations in the small-cap biotech universe this week, with a violent price surge colliding head-on with a rapidly building short position and a…
A 239% single-day rally in CNSP has detonated the lending market. CNS Pharmaceuticals' cost to borrow hit 326% on May 4 — up from 22.8% just one week earlier. That 1,170% weekly jump in borrow cost is the dominant…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CNSP — free to start on ORTEX.
Sign up for free →Open CNSP on ORTEX